<DOC>
	<DOCNO>NCT01984658</DOCNO>
	<brief_summary>This study prospective open phase-I study investigate safety tolerability administration repeat dos ALECSAT . Each patient follow 24 week initial blood donation last visit . However , actual treatment start day 26 , first single dose ALECSAT administer . The following administration give 3 week interval , i.e . week 7 10 . The patient attend Kirurgisk afdeling K , Bispebjerg Hospital , follow close examination study period regular visit complete study advise patient 's responsible physician .</brief_summary>
	<brief_title>A Prospective , Open Phase I Study Investigate Tolerability Efficacy ALECSAT Pancreas Cancer Patients</brief_title>
	<detailed_description>This study prospective open phase-I study investigate safety tolerability administration repeat dos ALECSAT . Each patient follow 24 week initial blood donation last visit . However , actual treatment start day 26 , first single dose ALECSAT administer . The following administration give 3 week interval , i.e . week 7 10 . The patient attend Kirurgisk afdeling K , Bispebjerg Hospital , follow close examination study period regular visit complete study advise patient 's responsible physician . The select group patient suffer locally advanced pancreatic cancer treat first line treatment regimen ( e.g . surgery , radiotherapy , and/or Folfirinox ) follow Kirurgisk afdeling K , Bispebjerg Hospital . The subject recruit consecutively include study fulfil inclusion criterion meet exclusion criterion . Potential candidate receive oral information Investigator subsequent write patient information . The potential candidate must opportunity consider give information ask Investigator question finally decide participate . When patient decides take part study he/she require sign declaration consent .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>Patients suffer locally advanced pancreatic cancer start treatment Folfirinox must stop side effect decline Folfirinox treatment . Minimum age 18 year old capable understanding information give informed consent , Minimum height 155 cm , Expected survival time ( life expectancy ) 6 month , Adequate performance status £ 2 ( see below* ) , Evident sign distant metastasis baseline Positive test antiHIV1/2 ; HBsAg , antiHBc , AntiHCV positive Treponema Pallidum test ( syphilis ) , Patient´s visit area outbreak West Nile virus Dengue virus within 28 day prior donation exclude , unless patient test negative , Concurrent illness , e.g . uncontrolled epilepsy , cardiovascular , cerebrovascular , and/or respiratory disease worsen cause complication connection blood donation , Clinically significant autoimmune disorder condition immune suppression , Haemoglobin count ≤ 7.5 mmol/l ( men &amp; woman ) , Lymphocytes 0.3 x 109/l , Clinically abnormal Erythrocyte Volume Fraction ( EVF ) , Body weight 40 kg ( men ) 50 kg ( woman ) , Pregnant breast feeding woman . Fertile woman include negative pregnancy test screening must use contraceptive study , Patients uncontrolled serious bacterial , viral , fungal parasitic infection , Blood transfusion within 48 hour prior donation blood ALECSAT production , Any medical condition render participation study risky , accord investigator make assessment study endpoint difficult ,</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>pancreatic cancer</keyword>
</DOC>